49
Participants
Start Date
February 28, 2006
Primary Completion Date
December 31, 2009
Study Completion Date
December 31, 2009
sorafenib tosylate
Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor targeting both tumor cells and the tumor vasculature. Patients with metastatic RCC meeting eligibility criteria will receive 400 mg BID of sorafenib in a single-arm phase II study. Treatment will be administered on an outpatient basis.
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
Baylor Sammons Cancer Center, Dallas
National Cancer Institute (NCI)
NIH
Case Comprehensive Cancer Center
OTHER